{"search_session":{},"preferences":{"l":"ar","queryLanguage":"ar"},"patentId":"107-912-938-465-83X","frontPageModel":{"patentViewModel":{"ref":{"entityRefType":"PATENT","entityRefId":"107-912-938-465-83X"},"entityMetadata":{"linkedIds":{"empty":true},"tags":[],"collections":[{"id":11748,"type":"PATENT","title":"University of Wuerzburg Patent Portfolio","description":"","access":"OPEN_ACCESS","displayAvatar":true,"attested":false,"itemCount":784,"tags":[],"user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"notes":[{"id":8387,"type":"COLLECTION","user":{"id":91044780,"username":"Cambialens","firstName":"","lastName":"","created":"2015-05-04T00:55:26.000Z","displayName":"Cambialens","preferences":"{\"usage\":\"public\",\"beta\":false}","accountType":"PERSONAL","isOauthOnly":false},"text":"
Search Applicants and Owners separately: uni* Wuerb*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 552
Search Applicants and Owners separately: uni* Wuerb*. Select more for logical variants. Add to collection. Select all patents in the collection and expand by simple families. Add to collection. Total patents: 552
(a) determining the level of PLD1 protein or pld1 transcript in thrombocytes;
(b) contacting said thrombocytes or thrombocytes of the same population with a test compound;
(c) determining the level of PLD1 protein or pld1 transcript in said thrombocytes after contacting with the test compound; and
(d) comparing the level of PLD1 protein or pld1 transcript determined in step (c) with the PLD1 protein or pld1 transcript level determined in step (a), wherein a decrease of PLD1 protein or pld1 transcript in step (c) as compared to step (a) indicates that the test compound is a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a disorder related to venous or arterial thrombus formation."],"number":9,"annotation":false,"title":false,"claim":true},{"lines":["A method of identifying a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a disorder related to venous or arterial thrombus formation, comprising the steps of:
(a) determining the level of PLD1-mediated integrin αllbβ3 activation in thrombocytes upon stimulation of the thrombocytes with an activator of PLD1;
(b) contacting said thrombocytes or thrombocytes of the same population with a test compound;
(c) determining the level of PLD1-mediated integrin αIIbβ3 activation in thrombocytes upon stimulation of the thrombocytes with an activator of PLD1 after contacting with the test compound; and
(d) comparing the level of PLD1-mediated integrin αIIbβ3 activation in thrombocytes upon stimulation of the thrombocytes with an activator of PLD1 determined in step (c) with the level of PLD1-mediated integrin αIIbβ3 activation in thrombocytes upon stimulation of the thrombocytes with an activator of PLD1 determined in step (a), wherein a decrease in the level of PLD1-mediated integrin αIIbβ3 activation in thrombocytes in step (c) as compared to step (a) indicates that the test compound is a compound suitable as a lead compound and/or as a medicament for the treatment and/or prevention of a disorder related to venous or arterial thrombus formation."],"number":10,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10, wherein the activation of integrin αIIbβ3 in thrombocytes is determined by measuring the amount of thrombocyte aggregation, the amount of fibrinogen binding or the amount of thrombocyte adhesion to von Willebrand factor under high shear flow conditions."],"number":11,"annotation":false,"title":false,"claim":true},{"lines":["The method of claim 10 or 11, wherein the activator of PLD1 is selected from the group consisting of GPlb-V-IX, GPVI, protease activated receptors 1 and/or 4, ADP receptors P2Y1 and P2Y12, CLEC-2 and thromboxane A2 receptor."],"number":12,"annotation":false,"title":false,"claim":true}]}},"filters":{"npl":[],"notNpl":[],"applicant":[],"notApplicant":[],"inventor":[],"notInventor":[],"owner":[],"notOwner":[],"tags":[],"dates":[],"types":[],"notTypes":[],"j":[],"notJ":[],"fj":[],"notFj":[],"classIpcr":[],"notClassIpcr":[],"classNat":[],"notClassNat":[],"classCpc":[],"notClassCpc":[],"so":[],"notSo":[],"sat":[]},"sequenceFilters":{"s":"SEQIDNO","d":"ASCENDING","p":0,"n":10,"sp":[],"si":[],"len":[],"t":[],"loc":[]}}